



220.001APC

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Nabel et al.
Appl. No. : 09/913,909
Filed : August 17, 2001
For : IMMUNIZATION FOR EBOLA
VIRUS INFECTION
Examiner : Foley, Shanon A.
Group Art Unit : 1648

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In response to the Restriction Requirement mailed October 15, 2003 in the above-identified application, Applicant responds as follows:

Restriction to one of the following groups was required under 35 U.S.C. 121:

Group I Claims 1-6, 9-13 and 22-26, drawn to a nucleic acid encoding an Ebola virus transmembrane form of virus glycoprotein, a first method of making and a first method of using.

Group II Claims 1-5, 7, 9, 14-17 and 22-26, drawn to a nucleic acid encoding an Ebola virus secreted form of virus glycoprotein, a first method of making and a first method of using.

Group III Claims 1-5, 8, 9 and 18-26, drawn to a nucleic acid encoding an Ebola virus nucleoprotein, a first method of making and a first method of using.

In response to the restriction requirement, Applicant elects Group I, that is, Claims 1-6, 9-13 and 22-26.

12/19/2003 SDENB001 00000026 09913909

01 FC:1251

110.00 OP

Appl. No. : 09/913,909
Filed : August 17, 2001


CONCLUSION

In view of the foregoing, Applicant respectfully requests that this application be passed to issuance. If any points remain that can be resolved by telephone, the Examiner is invited to contact the undersigned at the below-given telephone number.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 12/15/03

By: 
Nancy W. Vensko
Registration No. 36,298
Attorney of Record
Customer No. 20,995
(805) 547-5585

O:\DOCS\MXG\MXG-4203.DOC
121203